Recurrent Nasopharyngeal Carcinoma Clinical Trial
Official title:
Randomized Phase 2 Study of Nivolumab and Ipilimumab With or Without Cabozantinib in Patients With Advanced Nasopharyngeal Carcinoma That Have Progressed After Platinum Treatment and Immunotherapy
This phase II trial tests how well nivolumab and ipilimumab immunotherapy with or without cabozantinib in treating patients with nasopharyngeal cancer that has come back (after a period of improvement) (recurrent), has spread from where it first started (primary site) to other places in the body (metastatic), or for which no treatment is currently available (incurable). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Giving immunotherapy with nivolumab and ipilimumab and targeted therapy with cabozantinib may help shrink and stabilize nasopharyngeal cancer.
PRIMARY OBJECTIVE: I. To determine if the progression-free survival (PFS) of the triplet combination (cabozantinib S-malate, nivolumab, and ipilimumab [CaboNivoIpi]) is more favorable than the doublet (nivolumab and ipilimumab [NivoIpi]). SECONDARY OBJECTIVES: I. To compare safety and tolerability between the two arms (Common Terminology Criteria for Adverse Events [CTCAE] version [v]5.0.). II. To compare overall response rate (ORR) between the two arms via both Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and immune-modified Response Evaluation Criteria in Solid Tumors (iRECIST) criteria. III. To compare overall survival (OS) between the two arms. IV. To assess response by primary or acquired PD-1/L1 inhibitor resistance in the prior line of therapy. EXPLORATORY OBJECTIVE: I. To evaluate molecular and immunologic predictors of response (Epstein-Barr virus [EBV] viral load; PD-L1 score) between arms. OUTLINE: Patients are randomized to 1 of 2 arms. ARM A: Patients receive nivolumab intravenously (IV) over 30 minutes and ipilimumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography (CT) or magnetic resonance imaging (MRI) at baseline, every 3 cycles on treatment, and every 8-12 weeks during follow-up. Patients may also undergo collection of blood samples at baseline, day 1 of cycle 2, and at progression or end of treatment. ARM B: Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1 and cabozantinib S-malate orally (PO) daily on days 1-28 of each cycle. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients may continue with cabozantinib S-malate after 2 years per treating investigator. Patients undergo CT or MRI at baseline, every 3 cycles on treatment, and every 8-12 weeks during follow-up. Patients may also undergo collection of blood samples at baseline, day 1 of cycle 2, and at progression or end of treatment. After completion of study treatment, patients are followed up every 8-12 weeks until progression of disease occurs or a new non-protocol anti-cancer therapy is initiated and then every 6 months for up to 2 years. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03639467 -
Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT06029270 -
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
|
Phase 2 | |
Recruiting |
NCT03666221 -
Nimotuzumab for Recurrent Nasopharyngeal Carcinoma
|
Phase 2 | |
Recruiting |
NCT05350891 -
Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent NPC
|
Phase 2 | |
Active, not recruiting |
NCT04586088 -
Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure
|
Phase 2 | |
Active, not recruiting |
NCT04405622 -
Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.
|
Phase 2 | |
Recruiting |
NCT06235203 -
Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC
|
Phase 3 | |
Not yet recruiting |
NCT04215510 -
Early Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRT
|
Phase 3 | |
Recruiting |
NCT03930498 -
Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma
|
Phase 2 | |
Recruiting |
NCT03907826 -
PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients
|
Phase 3 | |
Recruiting |
NCT04376866 -
Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma
|
Phase 3 | |
Not yet recruiting |
NCT05432219 -
A Transoral Retropterygoid Approach to Resect Recurrent Nasopharyngeal Carcinoma
|
N/A | |
Recruiting |
NCT04425265 -
Plasma Radiofrequency Ablation at Low Temperature Versus Electrocautery Block Resection at High Frequency for Localized Recurrent Nasopharyngeal Carcinoma
|
N/A | |
Not yet recruiting |
NCT03689556 -
Examine the Prognostic Role of FLT PET/CT for Patients With LR-NPC Treated by Carbon Ion Therapy
|
||
Not yet recruiting |
NCT03210389 -
A Clinical Trial of Chemotherapy With Lobaplatin and 5-FU in Recurrent Local or Distant Advanced NPC.
|
Phase 2 | |
Completed |
NCT01370070 -
MK-2206 in Recurrent Nasopharyngeal Carcinoma
|
Phase 2 | |
Completed |
NCT01392235 -
Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC)
|
Phase 2 | |
Not yet recruiting |
NCT06228079 -
Adjuvant vs Surgery Only in Early-stage Recurrent NPC
|
Phase 3 | |
Terminated |
NCT04458909 -
Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer
|
Phase 3 | |
Withdrawn |
NCT04231864 -
Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer
|
Phase 2 |